Real‐world efficacy and potential mechanism of resistance of icotinib in Asian advanced non‐small cell lung cancer with EGFR uncommon mutations: A multi‐center study

The response to icotinib in advanced non‐small cell lung cancers (NSCLC) with EGFR uncommon mutation (EGFRum) is unclear. Here we reported the efficacy and potential resistance mechanism of icotinib in Chinese EGFRum NSCLC patients. Between July 2013 and November 2016, 3117 NSCLC patients were scree...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Med
Hauptverfasser: Lei, Lei, Wang, Wen‐xian, Zhu, You‐cai, Li, Jin‐luan, Fang, Yong, Wang, Hong, Zhuang, Wu, Zhang, Yin‐bin, Wang, Li‐ping, Fang, Mei‐yu, Xu, Chun‐wei, Wang, Xiao‐jia, Lv, Tang‐feng, Song, Yong
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2019
Schlagworte:
Clinical Cancer Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6943154/
https://ncbi.nlm.nih.gov/pubmed/31692291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2652
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge